Inhibition of guanosine monophosphate synthetase (GMPS) blocks glutamine metabolism and prostate cancer growth

Glutamine is a critical nutrient in cancer; however, its contribution to purine metabolism in prostate cancer has not previously been determined. Guanosine monophosphate synthetase (GMPS) acts in the de novo purine biosynthesis pathway, utilizing a glutamine amide to synthesize the guanine nucleotide. This study demonstrates that GMPS mRNA expression correlates with Gleason score in prostate cancer samples, while high GMPS expression was associated with decreased rates of overall and disease/progression-free survival. Pharmacological inhibition or knockdown of GMPS significantly decreased cell growth in both LNCaP and PC-3 prostate cancer cells. We utilized [N-15-(amide)]glutamine and [U-C-13(5)]glutamine metabolomics to dissect the pathways involved and despite similar growth inhibition by GMPS knockdown, we show unique metabolic effects across each cell line. Using a PC-3 xenograft mouse model, tumor growth was also significantly decreased after GMPS knockdown, highlighting the importance of glutamine metabolism and providing support for GMPS as a therapeutic target in prostate cancer. (c) 2021 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Automated summary

Glutamine is a critical nutrient in cancer, especially in prostate cancer; and Guanosine monophosphate synthetase (GMPS) plays a significant role in de novo purine biosynthesis pathway. High expression of GMPS is associated with decreased survival rates in prostate cancer, and inhibition or knockdown of GMPS can significantly decrease cell growth in prostate cancer cells. These findings highlight the importance of glutamine metabolism and suggest GMPS as a potential therapeutic target in prostate cancer.